Roche To Appeal NICE's Rejection Of Herceptin For HER2-positive Stomach Cancer

06 Jul 2010

• By John Davis

The latest appraisals from NICE include the rejection of Herceptin use in gastric cancer but give positive recommendations to RoActemra and TNF-inhibitors in rheumatoid arthritis.

Roche To Appeal NICE's Rejection Of Herceptin For HER2-positive Stomach Cancer

More from Archive

More from Pink Sheet